Article Text

Download PDFPDF

LSO-003 Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice
  1. Young Eun Kim1,
  2. Do Hoon Kim1,
  3. Mi Ryeong Jeong1,
  4. Eun-Ju Lee1,
  5. Soo Min Ahn1,
  6. Ji Seon Oh1,
  7. Seokchan Hong1,
  8. Chang-Keun Lee1,
  9. Bin Yoo1,
  10. Chang Ohk Sung2,
  11. Hyun Jae Shim3,
  12. Yoo Sook Cho3 and
  13. Yong-Gil Kim1
  1. 1Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea
  2. 2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea
  3. 3Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea


Background Progesterone-induced blocking factor 1 (PIBF1), a protein produced by maternal lymphocytes upon exposure to progesterone during pregnancy, acts as an immunomodulator by suppressing several immune pathway cytokines including Th1-based cytokines. Considering the female susceptibility to systemic lupus erythematosus, we aimed to determine the role of recombinant PIBF1 in the alleviation of lupus nephritis (LN) in MRL/MpJ-Faslpr/J (MRL/lpr) mice.

Methods MRL/lpr mice were ovariectomized at 6 weeks of age, and recombinant PIBF1 was administered intraperitoneally from 8 to 26 weeks of age (twice a week). Serum anti-dsDNA level was examined every 2 weeks from 8 to 24 weeks of age. The levels of serum cytokines at 16 and 24 weeks of age and urine albumin/creatinine (uACR) at 26 weeks of age were measured. At 26 weeks, the mice were sacrificed, and kidney biopsy was performed. Pathologic grading of disease activity and chronicity was performed by an animal pathologist according to the criteria of the NIH activity and chronicity indices. Additionally, splenocytes were analyzed by flow cytometry.

Results Serum anti-dsDNA level was increased in MRL/lpr mice that underwent ovariectomy; however, recombinant PIBF1 treatment attenuated the increase in anti-dsDNA autoantibodies (statistical significance after 18 weeks, p <0.05). uACR at 26 weeks was significantly decreased in the PIBF1-treated ovariectomy group compared with the PIBF1-untreated ovariectomy group (p <0.05). Furthermore, interstitial inflammation, global glomerulosclerosis, total activity index, and chronicity index scores were significantly decreased in PIBF1-treated mice compared with non-treated mice (figure 1). Analysis of splenocytes revealed that B220+CD4-CD8- T cells were decreased in PIBF1-treated mice compared with non-treated mice (p <0.05). However, the levels of serum cytokines including IL-2, IL-10, and IL-21 were not different between the two groups.

Conclusions Administration of recombinant PIBF1 attenuated the laboratory and histologic scores of LN-prone mice. Therefore, PIBF1 may function as an immunomodulator in LN.

Abstract LSO-003 Figure 1

Kidney tissues of MRL/lpr mice at 26 weeks. (A) Activity index. (B) Chronicity index. OVX, ovariectomy, *p < 0.05, **p < 0.01, ***p < 0.001

  • Progesterone-induced blocking factor
  • Systemic lupus erythematosus
  • Lupus nephritis

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.